Paratek Pharmaceuticals, Inc. announced revenue outlook for full year 2020. The company anticipates its full year 2020 total revenue to be at the higher end of the previously communicated range of $78 to $83 million driven by strong NUZYRA net revenue trends. This revenue guidance assumes that the initial BARDA procurement of NUZYRA, valued at approximately $38 million, will occur by the end of 2020. The FDA review could be completed as early as the end of this year but may slip into the first quarter of 2021. The first procurement is expected soon after completion of the FDA review. Accordingly, revenue from the first procurement will be recognized as early as late 2020 or in the first quarter of 2021.